Abstract: The invention relates to methods of treating antibody-mediated rejection in a subject comprising administering C1-INH to the subject according to a schedule with the following steps: (a) intravenously administering one or more iv-doses of C1-INH, (b) subcutaneously administering at least 10 sc-doses of C1-INH over several weeks, wherein each week at least one sc-dose is administered. The invention further relates to a method of treating antibody-mediated rejection in a transplant recipient comprising subcutaneously administering C1-INH over at least 10 weeks, wherein each week at least one sc-dose is administered.
Type:
Application
Filed:
November 18, 2021
Publication date:
January 4, 2024
Applicant:
CSL Behring GmbH
Inventors:
John Roberts, Marc Uknis, Christine Voigt
Abstract: The invention pertains to a blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings of patients having an acquired coagulation factor deficiency or for use in the treatment or prophylaxis of bleedings of patients having a congenital deficiency of a coagulation factor. Said product comprises at least isolated prothrombin (Factor II) and isolated Antithrombin III (ATIII), whereby the molar ratio between ATIII to Factor II is at least 1:30. By administration of said product the patient's risk for a thromboembolic complication is reduced.
Type:
Grant
Filed:
February 9, 2018
Date of Patent:
September 5, 2023
Assignee:
CSL Behring GmbH
Inventors:
Eva Herzog, Gerald Hochleitner, Oliver Grottke
Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
Type:
Grant
Filed:
March 20, 2019
Date of Patent:
April 13, 2021
Assignees:
CSL Behring GmbH, Universitaet Bern
Inventors:
Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
Type:
Application
Filed:
December 10, 2018
Publication date:
July 11, 2019
Applicant:
CSL Behring GmbH
Inventors:
Hung Pham, Jeffrey Michael Hey, Darren Nguy
Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
Type:
Grant
Filed:
March 7, 2014
Date of Patent:
May 14, 2019
Assignees:
CSL Behring GmbH, Universität Bern
Inventors:
Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
Type:
Grant
Filed:
April 28, 2016
Date of Patent:
June 5, 2018
Assignee:
CSL Behring GmbH
Inventors:
Stefan Zeitler, Marc Nolte, Stefan Schulte, Gerhard Dickneite, Ingo Pragst
Abstract: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.
Type:
Application
Filed:
November 9, 2017
Publication date:
May 3, 2018
Applicant:
CSL Behring GmbH
Inventors:
Hubert METZNER, Thomas WEIMER, Stefan SCHULTE
Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
Type:
Application
Filed:
June 14, 2017
Publication date:
September 28, 2017
Applicant:
CSL Behring GmbH
Inventors:
Stefan SCHULTE, Rolf SPIRIG, Sabine ZOLLNER, Michael MOSES, Wilfried WORMSBAECHER, Hans-Arnold STOEHR
Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
Type:
Application
Filed:
February 3, 2017
Publication date:
May 25, 2017
Applicant:
CSL Behring GmbH
Inventors:
Hung PHAM, Jeffrey Michael HEY, Darren NGUY
Abstract: Silent brain ischemia (SBI) or ischemia of other organs can result from an embolism that is introduced into the arterial system during a medical procedure. The application provides a method of administering a FXII inhibitor in a patient receiving a medical procedure and animal models useful for studying ischemia including SBI and ischemia in other organs, and for evaluating candidate therapeutics.
Type:
Grant
Filed:
March 9, 2012
Date of Patent:
April 18, 2017
Assignees:
The General Hospital Corporation, CSL Behring GmbH
Inventors:
Matthias Nahrendorf, Ralph Weissleder, Gerhard Dickneite, Guido Stoll, Marc Nolte
Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
March 21, 2017
Assignee:
CSL Behring GmbH
Inventors:
Hung Pham, Jeffrey Michael Hey, Darren Nguy